Model DetailsLung adenoma
Model Name |
Lung adenoma | Strain |
CD-1 |
Tumor Inducing Agent(s) |
Chemical/Drug : 3'-azido-3'-deoxythymidine (AZT) |
Tumor Synonym |
lung adenoma |
Strain Synonyms |
outbred CD-1 • Swiss CD-1® • CD1 nontransgenic • Charles River CD-1 • Swiss CD-1 • Crl:CD-1®(ICR) • outbred CD1 • (Swiss) CD-1 • CD1 • Crl:CD-1(ICR)BR • ICR Crj:CD-1 • random-bred Crl:CD-1(ICR)BR • CD-1 outbred • Crl:CD-1 (ICR) BR • Crj:CD-1(ICR) • ICR(CD-1) • Crl: CD-1 (ICR) BR • ICR |
| Organ Affected | Sex | Frequency | Age Of Detection | Additional Information Expand all Collapse all | Reference |
|---|---|---|---|---|---|
| Lung | Male |
8.7% (2 of 23 mice) |
180-400 days |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Lung | Male |
5.0% (1 of 20 mice) |
401 - ~725 days |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Lung | Male |
50% (4 of 8 mice) |
~730 days |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Lung | Male |
17.9% (5 of 28 mice) |
>400 days |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Lung | Male |
13.7% (7 of 51 mice) |
>180 days |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Lung | Male |
30.8% (8 of 26 mice) |
180-400 days |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Lung | Male |
9.1% (2 of 22 mice) |
401 - ~725 days |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Lung | Male |
33.3% (2 of 6 mice) |
~730 days |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Lung | Male |
14.3% (4 of 28 mice) |
>400 days |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Lung | Male |
22.2% (12 of 54 mice) |
>180 days |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Lung | Female |
4.8% (1 of 21 mice) |
180-400 days |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Lung | Female |
23.1% (3 of 13 mice) |
401 - ~725 days |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Lung | Female |
52.6% (10 of 19 mice) |
~730 days |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Lung | Female |
40.6% (13 of 32 mice) |
>400 days |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Lung | Female |
26.4% (14 of 53 mice) |
>180 days |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Lung | Female |
25% (6 of 24 mice) |
180-400 days |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Lung | Female |
41.2% (7 of 17 mice) |
401 - ~725 days |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Lung | Female |
30% (3 of 10 mice) |
~730 days |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Lung | Female |
37.0% (10 of 27 mice) |
>400 days |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Lung | Female |
31.4% (16 of 51 mice) |
>180 days |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |